Medtronic agrees to buy SPR Therapeutics for USD 650 million

Medtronic

Medtronic

MDT

0.00
  • Medtronic agreed to buy privately held SPR Therapeutics for about USD 650 million in upfront cash, adding temporary peripheral nerve stimulation technology for chronic pain.
  • The deal brings SPR’s FDA-cleared SPRINT PNS System, a 60-day percutaneous therapy that does not require a permanent implant, into Medtronic’s neuromodulation portfolio.
  • Closing is expected in the first half of Medtronic’s fiscal 2027, subject to customary closing conditions and regulatory approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medtronic plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605200915PR_NEWS_USPR_____CG63841) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.